Canberra. The Board of the peak body for more affordable medicines today announced its Chief Executive Officer of seven years, Ms Marnie Peterson, will complete her tenure at the end of 2025. The GBMA Board and members extend their sincere thanks to Marnie for her outstanding leadership, strategic foresight, and unwavering commitment to improving access to affordable medicines for all Australians.
The Independent Chair of the Generic and Biosimilar Association (GBMA), Hon. Professor Jane Halton AO PSM praised Ms Peterson for her leadership through some of the organisation’s most challenging and transformative years. “Over recent years, Marnie has collaborated closely with our members, stakeholders and government to manage global supply chain disruptions during the pandemic and was a pivotal negotiator in our five-year Strategic Agreement with Government. Marnie’s leadership has been instrumental in modernising the GBMA and elevating the role of our sector in the national health conversation”, says Professor Halton.
Ms Peterson has also held the position of CEO of GBMA Education to oversee the roll-out of the GBMA’s $5 million Biosimilar Education Grant and negotiations with the Department of Health, Disability and Aged Care, over reforms to further drive the uptake of biosimilar medicines.
“We’ve been incredibly fortunate to benefit from Marnie’s exceptional skillset, deep industry experience and calm, considered approach to negotiation. After many years of dedicated leadership, Marnie is stepping back, and we thank her for the immense contribution she has made”, says Professor Halton.
Ms Peterson will remain in her role as CEO until the end of December with plans for succession to be decided in due course.
Media inquiries: Jannette Cotterell Executive Counsel Australia
+61 419 204 059
jcotterell@executivecounsel.com.au
ABOUT GBMA
The Generic and Biosimilar Medicines Association (GBMA) is the peak representative body of generic and biosimilar medicine suppliers in Australia. Its members ensure that all Australians are offered the highest quality generic and biosimilar medicines in the world whilst providing affordable community health outcomes that benefit all Australians.
ABOUT BIOSIMILARS2
Biosimilar medicines are highly similar versions of the original, or ‘reference’, brand of a biological medicine. They are subject to the same regulatory standards and are equally safe and effective at treating the conditions as the original biological medicine.3
Biosimilar brands of medicine come onto the market after the patent for the equivalent reference brand of a biological medicine has expired. They provide more brand options for the same clinical results and introduce competition into the medicines market. They have been available in use for more than 15 years.
- https://www.aihw.gov.au/reports/australias-health/chronic-conditions
